Understanding the Rabies Threat and India’s Progress

Rabies remains a significant public health concern globally, particularly in regions like South Asia. Transmitted through the saliva of infected animals – most commonly dogs – rabies is almost invariably fatal once symptoms develop. Prevention relies heavily on prompt post-exposure prophylaxis (PEP), which includes wound cleaning and administration of the rabies vaccine and, in some cases, rabies immunoglobulin.

India has historically borne a disproportionately high burden of rabies cases, accounting for over a third of the world’s deaths. However, recent efforts have yielded encouraging results. In July, Dr. Manoj Murhekar of the ICMR-National Institute of Epidemiology reported a remarkable 75% reduction in rabies-related fatalities within the country. This progress is attributed to intensified dog vaccination campaigns and improved access to human rabies vaccines and monoclonal antibody treatments.

The Indian government has set an ambitious goal of eliminating rabies deaths by 2030. This strategy centers on widespread canine vaccination programs, aiming to break the chain of transmission, alongside enhanced availability of PEP in healthcare facilities nationwide. Dr. Murhekar emphasized the importance of ensuring rabies vaccines are readily accessible in every hospital, bolstering both preventative measures and emergency care capabilities.

Indian Immunologicals Ltd (IIL), the manufacturer of Abhayrab, has responded to the Australian advisory, characterizing it as “over-cautionary and misplaced.” The company states that only a single batch exhibited a packaging irregularity in January 2025, and this batch was immediately withdrawn from circulation. IIL maintains that all its vaccines undergo rigorous testing and are cleared by the Central Drugs Laboratory before release. Abhayrab has been in production since 2000, with over 210 million doses distributed across India and an additional 40 countries.

Did You Know?:

The debate surrounding the authenticity of the vaccine highlights the critical importance of robust supply chain management and quality control in the pharmaceutical industry. What measures can be implemented to further strengthen vaccine security and prevent the circulation of substandard or falsified products globally?

Furthermore, the incident raises questions about international communication protocols regarding potential public health risks. How can health organizations ensure swift and effective information sharing to protect travellers and vulnerable populations?

For more information on rabies prevention and treatment, consult the World Health Organization’s rabies fact sheet and the Centers for Disease Control and Prevention’s rabies page.

Frequently Asked Questions About the Rabies Vaccine Advisory

Q: What should I do if I received the Abhayrab vaccine in India after November 1, 2023?
A: The Australian Technical Advisory Group on Immunisation (ATAGI) advises consulting with a healthcare provider to discuss the possibility of receiving replacement doses with vaccines registered in Australia.

Q: Am I at risk if I received a rabies vaccination outside of India?
A: No, individuals who completed a full rabies vaccination course in other countries, including Australia, or have documented proof of a different vaccine brand are not affected by this advisory.

Q: What is IIL’s response to the claims of a counterfeit vaccine?
A: Indian Immunologicals Ltd (IIL) maintains that the alert is “over-cautionary and misplaced,” stating that only one batch showed a packaging anomaly and was promptly removed from circulation.

Q: What is India doing to eliminate rabies?
A: The Indian government is targeting the elimination of rabies deaths by 2030 through widespread dog vaccination and improved access to human rabies vaccines and monoclonal antibody treatments.

Q: How effective are rabies vaccines?
A: Rabies vaccines are highly effective in preventing the disease when administered promptly after exposure. Post-exposure prophylaxis (PEP) is crucial for preventing the development of symptoms.

Q: What are the symptoms of rabies?
A: Initial symptoms can include fever, headache, and general weakness. As the disease progresses, more severe neurological symptoms develop, ultimately leading to death.